🚀
Enjoy a 7-Day Free Trial Thru Dec 08, 2024!
✨
Sign Up
Login
Free Sign-up
Login
7-Day Free Trial
Home
Homepage
Membership Levels
About Us
General Discussion
Complete Stock List
The book
Membership Data Coverage
Founder's Message
Free Trial
Referral Program
Partner Program
GuruFocus Podcast
Screeners
GuruFocus Screeners
All-In-One Screener
Ben Graham Lost Formula
Canadian Faster Growers
CEO Buys
CEO Buys after Price Drop > 20%
Dividend Kings 2023
Dividend Aristocrats 2023
Dividend Growth Portfolio
Dividend Income Portfolio
Fast Growers
Good Companies
Hedge Fund Guru Top 10 Aggregated
High Quality
High Quality Low Capex w ROE ROC min
High Quality & Low Capex
High Yield Insider Buys
Historical High Dividend Yields
International Gurus' Top Holdings
James Montier Short Screen
Margin Decliners
Mega Caps
Peter Lynch & Warren Buffett
Peter Lynch Growth w Lower Valuation
Peter Lynch S&L Traded Below Book
PFCF Screener
Piotroski Score Screener
Predictable Growth Companies
Profitable predictable margin expanders
Stocks Sold w less Cash
The Stalwarts
My Screeners
Create My Screener
Value Screens
Stock Ideas
All-In-One Screener
S&P 500 Map
S&P 500 Bubble
S&P 500 Aggregate
Buffett-Munger Screener
Industry Overview
Undervalued Predictable
Benjamin Graham Net-Net
52-week/3Y/5Y Lows
52-week/3Y/5Y Highs
Magic Formula(Greenblatt)
Dividend Stocks
Peter Lynch Screen
S&P500 Grid
Predictable Companies
Spin Off List
Merger and Acquisition List
Historical Low P/B List
Historical Low P/S List
High Short Interest
Upcoming Special Dividends
Delisted Stocks
Model Portfolios
Performances Overview
Most Broadly Held Portfolio
Most Weighted Portfolio
Buffett-Munger Top 25
GF Score <= 100 Top 25
Top 25 Undervalued Predictable
Top 25 52-week Low Predictable
Top 25 Historical Low P/S
Stock Comparison
Airline Stocks
Artificial Intelligence Stocks
Bank Stocks
Biotech Stocks
Blockchain Stocks
Chinese Stocks
Dividend Stocks
EV Stocks
Growth Stocks
Oil Stocks
Value Stocks
Virtual Reality Stocks
Compare More Stocks…
Gurus
Guru Trades
Latest Guru Picks
Real Time Picks
Guru Portfolio
Score Board
Mutual Funds
Top 10 Holdings
Sector Picks
International Picks
Aggregated Portfolio
Consensus Picks
Guru Bargains
Hot Picks
Download Guru Portfolios
Industry Trends
Geographic Trend
ETFs
Options Holdings
European Shorting
Guru Lists
Complete Guru List
Warren Buffett
Bill Gates
Mohnish Pabrai
Carl Icahn
George Soros
David Tepper
Seth Klarman
Bill Ackman
Joel Greenblatt
Charlie Munger
Michael Price
Julian Robertson
Chuck Akre
David Einhorn
Tom Gayner
My Guru Lists
Insiders
Insider Trading Tracker
Real-Time Insider Picks
CEO Buys/Sells
CFO Buys/Sells
Insider Trends
Insider Cluster
Guru + Insider Double Buys
Triple Buys/Sells
Canadian Insider
Chinese Insider
German Insider
Complete Insider List
Politician Trading Tracker
Real-Time Politician Picks
Complete Politician List
Nancy Pelosi
Mitch Mcconnell
Tommy Tuberville
Josh Gottheimer
Kevin Hern
Thomas R. Carper
Susie Lee
Lois Frankel
Market
US Market Valuation
Buffett Indicator
U.S. Treasury Yield Curve
U.S. Inflation Rate
Presidential Cycle and Stock Market
Shiller P/E
Shiller P/E by Sectors
GF Value for S&P 500 Index
Fed Net Liquidity
Buffett Assets Allocation
Latest IPOs
Global Market Valuation
Global Market Overview
USA
China
Japan
India
Canada
UK
France
Germany
Brazil
Australia
More...
Economic Indicators
Economic Indicators Overview
The Dow Jones Industrial Average (DJIA)
SP 500 Index
Nasdaq Composite Index
Gross Domestic Product (GDP)
Shiller PE
Ratio of Wilshire 5000 over GNP
Civilian Unemployment Rate
Russell 2000 Index
CBOE Volatility Index (VIX)
Total Nonfarm Payrolls: All Employees
More...
Sector & Industry Performance
Global Industry Overview
USA
Asia
Europe
Canada
UK/Ireland
Oceania
Latin America
Africa
India/Pakistan
Articles
Articles
Editors' Picks
Stock Market News
Q&A with Gurus
Guru Stock Picks
Insider Transaction
Earning Reports
Podcast
Earnings Call Transcripts
Software Stock News
Biotechnology Stock News
Hardware Stock News
Banks Stock News
Metals & Mining Stock News
Drug Manufacturers Stock News
All Articles
Submit Articles
Submit Article Online
Contributor Guidelines
Tools
Model Portfolios
All-In-One Screener
Data Batch Download
Guru Portfolio Download
Insider Data Download
Excel Add-In
Google Sheets Add-On
API
Manual of Stocks
DCF Calculator
WACC Calculator
Interactive Chart
Maps
Fund Letters Archive
Stock Comparison Table
Mobile App
Discussion Board
GuruGPT
Financial Calendar
Embed Widgets
Stock Market Holidays
Discussion
Discussion Board
Data
Pricing
Tutorials
Tutorials
Financial Glossary
FAQ
Change Log
Contact Us
Support
Chat Support
Create a ticket
Book Demo
User Engagement Meeting
469-248-6885
Status
Take Survey
Subscribe
Free Trial
Group Subscription
Refer a Friend and Earn One Month of Free Membership
GURUFOCUS.COM
STOCK LIST
Healthcare
Drug Manufacturers
Gilead Sciences Inc (MEX:GILD)
News
Gilead Sciences Inc
MEX
:GILD (USA) Â
Ordinary Shares
MXN 1892.40
(0%)
Nov 29
On watch
P/E:
1,028.67
P/B:
6.24
Market Cap:
MXN 2.36T
($ 115.86B)
Enterprise V:
MXN 2.73T
($ 134.15B)
Volume:
-
Avg Vol (2M):
989.00
Warning! GuruFocus detected 2 Severe warning signs with GILD.
Try a 7-Day Free Trial
to check it out.
Trade In:
Volume:
-
Market Cap MXN:
2.36T
Market Cap $:
115.86B
PE Ratio:
1,028.67
Avg Vol (2M):
989.00
Enterprise Value MXN:
2.73T
Enterprise Value $:
134.15B
PB Ratio:
6.24
Alerts
Website
Sources
Stock PDF
Dataset
Financial Download
Manual of Stocksâ„¢
Compare
0
Summary
30-Y Financials
Estimates
DCF
Dividend
Guru Trades
Insider
Interactive Chart
Transcripts
News
Compare
Stock PDF
Ownership
Operating
Checklist
Vote
Definitions
Gilead Sciences Inc (MEX:GILD) Stock News, Headlines & Updates
Gilead Sciences Inc Stock News from GuruFocus
Total 40
1
Nov 27, 2024
Gilead Sciences Inc (GILD) Announces Promising Results from Phase 3 HIV Prevention Trial
GuruFocus News
•
5:54pm
Gilead Announces New England Journal of Medicine Publication of PURPOSE 2 Results
Business Wire
•
5:00pm
Nov 26, 2024
Gilead Sciences: Designing Inclusive Clinical Trials in an Effort To Upend the HIV Epidemic
ACCESSWIRE
•
11:00am
Nov 22, 2024
Gilead Announces Layoffs Amid Strong Q3 Performance, HIV Drug Sales Surge
GuruFocus News
•
1:30pm
Nov 21, 2024
Gilead Sciences (GILD) Announces Issuance of Senior Notes in New Indenture Agreement
GuruFocus News
•
7:00pm
Nov 15, 2024
Gilead's Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
Business Wire
•
11:00am
Nov 14, 2024
Gilead Prices $3.5 Billion of Senior Unsecured Notes
Business Wire
•
8:00pm
Nov 13, 2024
Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow
Business Wire
•
6:00am
Decoding Gilead Sciences Inc (GILD): A Strategic SWOT Insight
GuruFocus News
•
11:04pm
Nov 12, 2024
Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
Business Wire
•
5:00am
Nov 08, 2024
Gilead Sciences to Present at Upcoming Investor Engagements
Business Wire
•
4:00pm
Gilead Sciences (GILD) Target Price Raised by BMO Capital
GuruFocus News
•
3:31am
Nov 07, 2024
Gilead Sciences Inc (GILD) Shares Up 5.1% on Nov 7
GuruFocus News
•
10:07am
Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic
Business Wire
•
8:00am
Gilead Sciences (GILD) Shares Surge on Strong Q3 Earnings and Raised Forecast
GuruFocus News
•
7:32am
Gilead Sciences Inc (GILD) Q3 2024 Earnings Call Highlights: Strong HIV and Oncology Sales Drive Growth Amid Competitive Challenges
GuruFocus News
•
1:20am
Q3 2024 Gilead Sciences Inc Earnings Call Transcript
GuruFocus News
•
11:10pm
Nov 06, 2024
Gilead Sciences Announces Third Quarter 2024 Financial Results
Business Wire
•
4:00pm
Nov 05, 2024
Kite to Highlight Industry-Leading CAR T-Cell Therapy Portfolio at ASH 2024, Including Positive Survival Outcomes in Both Clinical Trials and the Real-World
Business Wire
•
9:00am
Oct 31, 2024
Gilead Oncology Grant Supports 22 U.S. Organizations With $3.15 Million to Provide Support to Those Affected By Breast Cancer
ACCESSWIRE
•
11:00am
Oct 22, 2024
Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024
Business Wire
•
9:00am
Oct 09, 2024
Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024
Business Wire
•
4:00pm
Gilead Sciences Inc (GILD) Q2 2024 Earnings Call Highlights: Strong Growth in HIV and Oncology Segments
GuruFocus News
•
3:52pm
Q2 2024 Gilead Sciences Inc Earnings Call Transcript
GuruFocus News
•
1:44pm
Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024
Business Wire
•
8:00am
Oct 08, 2024
Gilead Sciences: New Report Shows Every Country in the World Must Do More To End the HIV Epidemic
ACCESSWIRE
•
11:00am
Oct 07, 2024
Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference
Business Wire
•
11:00am
Oct 03, 2024
Insider Sale: Chief Medical Officer Merdad Parsey Sells 2,000 Shares of Gilead Sciences Inc (GILD)
GuruFocus News
•
7:04pm
Oct 02, 2024
Hetero Signs Voluntary Licensing Agreement with Gilead to Transform Global HIV response, Expanding Access to Groundbreaking Lenacapavir to 120 high-incidence countries
PRNewswire
•
10:00am
Gilead Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries
Business Wire
•
8:00am
Sep 25, 2024
Championing HIV Services for LGBTQ+ Youth
ACCESSWIRE
•
11:00am
Sep 18, 2024
Working to Build Next-Generation Cancer Therapies
ACCESSWIRE
•
3:00pm
Sep 14, 2024
Insider Sale: Johanna Mercier Sells 29,357 Shares of Gilead Sciences Inc (GILD)
GuruFocus Research
•
11:51pm
Sep 12, 2024
Helping End HIV - Gilead Sciences
ACCESSWIRE
•
11:00am
Gilead's Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial
Business Wire
•
8:00am
Sep 10, 2024
Seramount Ranks Gilead Sciences Among Its Leading Inclusion Index Company
ACCESSWIRE
•
11:00am
Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies
Business Wire
•
8:00am
Sep 06, 2024
Gilead Sciences: Living With a Rare Liver Disease: Maria's Journey
ACCESSWIRE
•
11:00am
Sep 05, 2024
Gilead to Present New Trodelvy® Data at the IASLC 2024 World Conference on Lung Cancer
Business Wire
•
8:00am
Sep 04, 2024
Gilead Sciences: Innovative Approaches to Healthcare Can Remove Barriers
ACCESSWIRE
•
11:00am
Total 40
1
Show
20
40
60
80
100
No data
Entries
Headlines
Total 0
1
No recent news